300
Participants
Start Date
January 31, 2004
Primary Completion Date
November 30, 2006
Study Completion Date
November 30, 2006
Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)
"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
Many Locations
Genzyme, a Sanofi Company
INDUSTRY